Motley Fool Australia
  •  
  • Log Out
  • Menu
  1. Stocks
    2. /
  2. Johnson & Johnson (NYSE: JNJ)
    3. /

Johnson & Johnson (NYSE: JNJ) Share Price and News

$154.14 $-0.08 (-0.1%) Tuesday, 13 May 2025 at 6:00:00 am Australian Eastern Standard Time

Johnson & Johnson Chart and Price Data

Created with Highcharts 11.4.3Johnson & Johnson PriceZoom1M3M6MYTD1Y5Y10YALL→www.fool.com.au

About Johnson & Johnson

Last updated 13-05-2025, 06:00:00am AEST
Current Price $154.14
Change $-0.08 (-0.1%)
Close Price $154.14
Open Price $152.02
Bid $153.00
Ask $154.49
Day Range $151.18 - $155.36
Year Range $140.68 - $169.99
Volume 9,023,782
Average Volume 9,685,418
Market Cap $371,454,279,000.00
Earnings Per Share $9.00

    • Johnson & Johnson (NYSE: JNJ)
    Latest News

    Anacacia Capital portfolio manager Oscar Hutchinson
    Ask a Fund Manager

    4 ASX shares to gain exposure to international market growth: fund manager

    | Bernd Struben

    Investing in international shares is a different ball game. Let's hear from an expert.

    Read more »

    Investor happily looking at rising share price on laptop.
    Investing Strategies

    5 international value shares with a positive outlook: analyst

    | Bernd Struben

    Aussie investors looking to diversify their share portfolios could consider investing some of their funds overseas.

    Read more »

    US 100 dollar notes with a gavel on top of it
    International Stock News

    Supreme Court rules Johnson & Johnson must pay $2.1 billion in baby powder lawsuit

    | Eric Volkman

    The company has set aside nearly $4 billion as a "litigation expense."

    Read more »

    Platinum Asset Management's Dr Bianca Ogden
    Ask a Fund Manager

    This fundie has a PhD in healthcare: now she invests in it

    | Tony Yoo

    Ask A Fund Manager: Platinum Asset Management's Dr Bianca Ogden tells how she used to work for the company that's…

    Read more »

    Covid-19 vaccine
    International Stock News

    How Johnson & Johnson beat expectations in Q1

    | Keith Speights

    The healthcare giant saw a marked recovery from the negative impacts of the COVID-19 pandemic.

    Read more »

    A line of people sitting at a long desk in an annual general meeting
    International Stock News

    2 things investors need to look for in Johnson & Johnson's earnings tomorrow

    | Alex Carchidi

    Formally addressing the recent challenges will help to put shareholders at ease again.

    Read more »

    health worker holding a vaccine in their hand
    International Stock News

    The Johnson & Johnson COVID vaccine halt: here's what investors need to know

    | Adria Cimino

    Officials are investigating "severe" blood clots in some people.

    Read more »

    health worker wearing personal protective equipment and gesturing stop with her hands
    International Stock News

    U.S. gives Johnson & Johnson's COVID-19 vaccine a timeout

    | Cory Renauer

    Out of an abundance of caution, the FDA and CDC have recommended a pause in the use of the only…

    Read more »

    Five different pggy banks, indicating a diverse share portfolio
    ETFs

    2 top ASX ETFs to buy right now

    | Sebastian Bowen

    The iShares S&P 500 ETF (ASX: IVV) is one of two ASX ETFs to buy today for ASX share portfolio…

    Read more »

    coronavirus vaccine represented by gloved hand drawing down from syringe
    International Stock News

    Johnson & Johnson coronavirus vaccine wins FDA authorisation

    | Eric Volkman

    The big pharmaceutical company's jab has some important advantages.

    Read more »

    Cash piled up in the middle of a bear trap symbolising risky investments
    International Stock News

    Why Moderna Is Less Risky Than You Think

    | Manali Bhade

    Its coronavirus vaccine will likely be successful; its technology has huge potential; and the company has a healthy balance sheet.

    Read more »

    doctor giving little boy vaccine injection in his arm
    International Stock News

    Johnson & Johnson (NYSE:JNJ) starts late-stage coronavirus vaccine clinical trial

    | Brian Orelli, PhD

    The phase 3 study of JNJ-78436735, which will enroll 60,000 participants, is underway.

    Read more »

    Profile

    since

    Note